| 发明名称 |
Dosages of Immunoconjugates of Antibodies and SN-38 for Improved Efficacy and Decreased Toxicity |
| 摘要 |
The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. |
| 申请公布号 |
US2016090423(A1) |
申请公布日期 |
2016.03.31 |
| 申请号 |
US201514955469 |
申请日期 |
2015.12.01 |
| 申请人 |
Immunomedics, Inc. |
发明人 |
Govindan Serengulam V.;Goldenberg David M. |
| 分类号 |
C07K16/30;A61K39/395;A61K47/48;A61K45/06 |
主分类号 |
C07K16/30 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A method of treating breast, lung, pancreatic, esophageal, medullary thyroid, ovarian, uterine, prostatic, testicular, colon, rectal or stomach cancer comprising administering to a human subject with breast, lung, pancreatic, esophageal, medullary thyroid, ovarian, uterine, prostatic, testicular, colon, rectal or stomach cancer an immunoconjugate comprising SN-38 conjugated to an hMN-14 (anti-CEACAM5) antibody or antigen-binding fragment thereof; wherein the immunoconjugate is administered at a dosage of between 3 mg/kg and 18 mg/kg. |
| 地址 |
Morris Plains NJ US |
